On the 21st Feb 2025, Mayne Pharma (MYX AU) entered into a Scheme with US-based pharmaceutical outfit, Cosette Pharmaceuticals, at A$7.40/share. Then the wheels fell off.
As discussed in Mayne Pharma (MYX AU): This One’s On You Jim As Court Dismisses Cosette’s Appeal, if not for the Treasurer dinging the deal, Cosette had no legal out.
Mayne has now entered into a SID with Gedeon Richter (0QFP LN) at A$6.40/share, a punchy 99.4% premium to undisturbed. Looks clean. Expected implementation late March 2027.
Mayne Pharma (MYX AU) is not super illiquid - look away now if this is not your thing.
The Trade:
At A$5.92/share, I see the current/gross spread of 8.1%/23.7%, assuming late March completion.
That’s attractive.
Risk to the deal is one of timing, as it relates to various reg approvals.

